# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-23-205262
Filing Date
2023-08-08
Accepted
2023-08-07 21:51:27
Documents
3
Period of Report
2023-08-07

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | d520772dpre14a.htm | PRE 14A | 869164
2 | GRAPHIC | g520772g00a02.jpg | GRAPHIC | 55749
3 | GRAPHIC | g520772g00a56.jpg | GRAPHIC | 692386
| Complete submission text file | 0001193125-23-205262.txt |  | 1892144

Mailing Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37722 | Film No.: 231149125
SIC: 2834 Pharmaceutical Preparations